Curis, Inc. (CRIS) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
14.87
↑+79% vs avg
5yr avg: 8.30
30Y Low0.9·High23.9
ROE
↓
-138.8%
↓+33% vs avg
5yr avg: -208.1%
30Y Low-365%·High-11%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CRIS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Curis, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $81M | $130M | $19M | $67M | $51M | $436M | $399M | $56M | $23M | $104M | $409M |
| Enterprise Value | $78M | $127M | $2M | $44M | $36M | $401M | $277M | $41M | $35M | $108M | $403M |
| P/E Ratio → | -1.06 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.60 | 13.80 | 1.77 | 6.73 | 5.05 | 40.93 | 36.79 | 5.64 | 2.19 | 10.55 | 54.34 |
| P/B Ratio | 14.87 | 23.86 | — | 3.43 | 1.10 | 4.81 | 3.05 | — | — | 4.35 | 13.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CRIS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.44 | 0.21 | 4.35 | 3.51 | 37.65 | 25.53 | 4.11 | 3.33 | 10.88 | 53.51 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CRIS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Curis, Inc. earns an operating margin of -348.4%. Operating margins have expanded from -482.2% to -348.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -138.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.5% | 99.5% | 99.1% | 97.9% | 97.5% | 95.0% | 95.1% | 95.0% | 94.6% | 95.0% | 94.7% |
| Operating Margin | -348.4% | -348.4% | -408.3% | -482.2% | -521.7% | -395.0% | -229.8% | -243.5% | -281.3% | -502.7% | -771.1% |
| Net Profit Margin | -80.3% | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% | -276.0% | -321.3% | -312.4% | -538.7% | -802.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -138.8% | -138.8% | -634.7% | -143.2% | -82.6% | -41.0% | -61.8% | — | -334.2% | -200.2% | -128.8% |
| ROA | -24.8% | -24.8% | -73.2% | -50.9% | -41.8% | -24.8% | -25.0% | -88.7% | -58.6% | -81.1% | -79.1% |
| ROIC | — | — | — | -272.4% | -91.9% | -97.9% | — | — | -127.1% | -148.2% | -110.7% |
| ROCE | -233.9% | -233.9% | -114.9% | -62.7% | -42.8% | -24.5% | -22.3% | -81.8% | -64.7% | -91.5% | -84.2% |
CRIS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | — | 0.14 | 0.08 | 0.06 | 0.06 | — | — | 1.73 | 0.68 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | — | -1.21 | -0.34 | -0.39 | -0.93 | — | — | 0.14 | -0.21 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -15.06 | -15.06 | -69.55 | -22.48 | -10.88 | -9.16 | -4.87 | -5.63 | -7.30 | -12.44 | -20.75 |
Net cash position: cash ($5M) exceeds total debt ($2M)
CRIS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.36x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.77x to 0.36x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.36 | 0.36 | 1.39 | 2.77 | 9.20 | 9.11 | 17.14 | 3.82 | 4.25 | 4.56 | 5.44 |
| Quick Ratio | 0.36 | 0.36 | 1.39 | 2.77 | 9.20 | 9.11 | 17.14 | 3.82 | 4.38 | 4.56 | 5.59 |
| Cash Ratio | 0.36 | 0.36 | 1.05 | 2.56 | 8.55 | 8.62 | 16.72 | 3.14 | 3.81 | 4.27 | 5.16 |
| Asset Turnover | — | 0.47 | 0.26 | 0.13 | 0.09 | 0.07 | 0.05 | 0.28 | 0.28 | 0.13 | 0.13 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 112.06 | 101.75 | 106.86 | 110.50 | 102.51 | 118.36 | 100.25 | 113.32 | 119.24 |
CRIS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Curis, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $132M | $6M | $5M | $5M | $5M | $2M | $2M | $2M | $1M | $1M |
Peer Comparison
Compare CRIS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CRISYou | $81M | -1.1 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 TGTX | $7B | 15.2 | 55.7 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 KPTI | $78M | -0.5 | — | — | 95.9% | -62.1% | — | — | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 PRTA | $602M | -2.5 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
See CRIS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRIS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRIS vs TGTX
Side-by-side business, growth, and profitability comparison vs TG Therapeutics, Inc..
Start ComparisonCRIS — Frequently Asked Questions
Quick answers to the most common questions about buying CRIS stock.
What is Curis, Inc.'s P/E ratio?
Curis, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Curis, Inc.'s ROE?
Curis, Inc.'s return on equity (ROE) is -138.8%. The historical average is -89.4%.
Is CRIS stock overvalued?
Based on historical data, Curis, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Curis, Inc.'s profit margins?
Curis, Inc. has 99.5% gross margin and -348.4% operating margin.